Medicine and Health Sciences Commons^™

Proteomic Analysis Of Stress Associated Factor Overexpression In Hepatocellular Carcinoma, Mohammad Shabir Hussain, Sophia Leslie, Amayrani Sanchez, Samantha Lopez, Kyle Doxtater, Manish Kumar Tripathi

Research Symposium

Background: Hepatocellular carcinoma (HCC) constitutes a substantial portion, accounting for 85% to 90% of liver cancers worldwide. Notably, within the Hispanic population, liver cancer mortality rates are notably higher, particularly evident in regions like the South Texas Rio Grande Valley (RGV), where nearly 90% of the populace is Latino/Hispanic. This region grapples with poverty affecting nearly 30% of its residents, coupled with elevated rates of obesity, diabetes, and low-income households, thereby fostering a prevalent environment of stress. Stress can profoundly impact cancer outcomes by compromising immune functionality and triggering inflammatory responses, potentially impairing surveillance against oncogenic triggers. The activation of …

Hepatoprotective Role Of Cucurbitacin D On Benzo[A]Pyrene Induced Liver Injury, A. Rodriguez, Mohammed Sikander, Shabnam Malik, M. Vela, Fathi T. Halaweish, Meena Jaggi, Sumeet S. Chauhan

Research Colloquium

Background: Epidemiological findings show the strong correlation of co-morbidity factors including smoking with the development and progression of liver cancer. Moreover, benzo[a]pyrene, a main component of tobacco smoke, is extremely carcinogenic and contributes to liver injury as well. Cucurbitacin, chemically classified as triterpenes, have shown diverse biological activities including potent antioxidant, anti-inflammatory and anti-cancer activities. However, their hepatoprotective activities are not completely understood.

Objective: In the present study, we investigated the cytoprotective activity of novel analog of cucurbitacin, cucurbitacin D, against benzo[a]pyrene-induced liver injury in human HepG2 cells.

Method: Proliferation, clonogenicity, migration, invasion, Western blotting and qPCR analysis were conducted …

Mucin 13 Expression Correlates With Tumor Development In Hepatocellular Carcinoma, Shabnam Malik, Mohammed Sikander, Deepshikha Pande Katare, S. Mishra, S. K. Jain, P. Khan, Subhash C. Chauhan, Meena Jaggi

Research Colloquium

Background: Hepatocellular carcinoma (HCC) has a poor prognosis due to ineffective therapeutic modality and lack of early diagnostic marker. Accumulating studies have shown that elevated expression of mucin 13 as potential oncogene and predictive biomarker for various cancer. However, very little is known about its expression and function for development and progression of HCC Objective: To investigate mucin 13 expression in chemically induced hepatocellular carcinoma model.

Methodology: Diethyl nitrosamine (DEN) and 2-Acetylaminofluorene (2-AAF) induced method was employed for the development of hepatocellular carcinoma in Male Wistar rats. Serum and tissues were collected at regular interval of time and routinely validated …

Long Non-Coding Rna (Lncrna) As A New Biomarker For Hepatocellular Carcinoma (Hcc) Drug Resistance, Areeb Masood, Kyle Doxtater, Anupam Dhasmana, Subhash C. Chuahan, Sanjaya Satapathy, Manish Tripathi

Research Symposium

Background: Hepatocellular carcinoma (HCC) is the 4^th leading cause of cancer-related deaths worldwide and the 6^th most common cancer worldwide. When HCC progresses to advanced stages, drug resistance becomes a major hurdle and leaves clinicians with limited therapeutic options. Long non-coding RNAs (lncRNAs) have shown to promote drug resistance in various cancers. The goal of our research is to explain the molecular role of lncRNAs in HCC drug resistance and compile a comprehensive list of studied lncRNAs involved in HCC drug resistance.

Methods: To compile a list of lncRNA involved in HCC drug resistance we performed an advanced …

Ybx1 Modulates Drug Resistance In Liver Cancer, Ana G. Ayala Pazzi

Research Symposium

According to the Texas Cancer Registry, hepatocellular carcinoma (HCC) is the sixth most common cause of cancer death. In 2015, Texas had the country's highest incidence rate and the fourth highest mortality rate. Texas Hispanics (87% of Mexican origin) showed the highest incidence and mortality rates compared to the overall US Hispanic population, with individuals of Mexican origin having the highest rates. The Rio Grande Valley, which is predominantly Mexican, is extremely affected by this fact, which exacerbates the need to address this issue within our community.

A major challenge in improving patient therapy in liver cancer is Sorafenib resistance. …

Rare Presentation Of Metastatic Hepatocellular Carcinoma In The Finger: Case Report And Review Of Literature, F. Rhana Mousavi, Bassem Bekheit, Emon Alavi, Nick A. Hirad, Abanoub Gabra

Research Day

Hepatocellular carcinoma (HCC) is a primary tumor of the liver that primarily develops in the setting of chronic liver disease. HCC is difficult to diagnose due to it requiring the use of multiple imaging modalities with the goal to detect tumors when they are less than or equal to 2 cm in size to allow all possible treatment options to be used. Herein, we discuss a 69-year-old male with stage IV liver cancer residing in hospice presenting with left middle finger osteomyelitis and extreme pain. Radiology revealed a destructive lesion but pathology provided the diagnosis of metastatic hepatocellular carcinoma in …

In Patients With Hepatocellular Carcinoma (Hcc) (P), Is Bevacizumab With Atezolizumab (I) More Effective Than Sorafenib (C) In Long-Term Clinical Prognosis (O)?, Joon Lee

Capstone Showcase

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally. China contributes to half of the global incidence of liver cancer, with about 70-85% being HCC. Definitive treatment for this condition would be surgical resection with liver transplant but for obvious reasons, the majority of affected patients are unable to meet the necessary criteria. Sorafenib is a form of chemotherapy that has been the mainstay treatment of HCC since its approval in 2007. More recently, the combination of Bevacizumab and Atezolizumab has shown greater efficacy in the treatment of unresectable HCC. Additionally, this new combination therapy shows favorable …